Active substances
Dapagliflozin + Saxagliptin
- SFDA 1
- US FDA 3
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ENFORZA | 10,5 mg,mg | Film-coated tablet · Oral use | 30 Jar | SAR 214.75 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE | 10MG;EQ 5MG BASE | tablet · oral | MSN | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE | 10MG;EQ 5MG BASE | tablet · oral | TORRENT | Prescription | 6 Apr 2026 |
| QTERN | 10MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 5MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ASTRAZENECA AB | Discontinued | 27 Feb 2017 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Saxagliptin 5mg / Dapagliflozin 10mg tablets | £49.56 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.